Avenues Counseling, Llc Counselor Medicare: Not Enrolled in Medicare Practice Location: 1118 15th Ave, Monroe, WI 53566 Phone: 608-325-1070 Fax: 608-325-1070 |
Lotus Counseling & Consulting Llc Counselor Medicare: Not Enrolled in Medicare Practice Location: 2439 5th St, Monroe, WI 53566 Phone: 608-312-3132 |
Mainstreet Counseling Clinic - Mental Health Medicare: Medicare Enrolled Practice Location: 1717 11th St, Monroe, WI 53566 Phone: 608-214-6225 |
Paladin Counseling & Consultation, Llc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 819 1st Ave, Monroe, WI 53566 Phone: 608-325-5520 Fax: 608-325-5846 |
Affinity Counseling Llc Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1209 17th Ave, Monroe, WI 53566 Phone: 608-426-6463 |
News Archive
An estimated 30 percent of outpatient oral antibiotic prescriptions in the U.S. in 2010-2011 may have been inappropriate, findings that support the need for establishing a goal for outpatient antibiotic stewardship, according to a study appearing in the May 3 issue of JAMA.
Research shows that the combination of daclatasvir and sofosbuvir leads to high rates of sustained virologic response in patients with chronic hepatitis C virus infection, including those who have not responded to previous therapy.
Niiki Pharma Inc. announced interim results from the ongoing Phase I clinical trial of its lead product, NKP-1339. NKP-1339 is a first-in-class transferrin targeted small molecule that down-regulates GRP78, a key regulator of mis-folded protein processing and a tumor survival factor.
The National Association of Psychiatric Health Systems has published a 2011 Membership Directory. The directory is a comprehensive referral resource providing information on the nation's behavioral healthcare systems.
ZIOPHARM Oncology, Inc. announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to pharmaceutical compositions of a novel DNA cross-linker, including palifosfamide and their use in treating cancer.
› Verified 5 days ago